Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.00 | 0.12% | 827.50 | 7,672 | 08:32:36 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 825.50 | 828.50 | 837.00 | 815.00 | 815.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 1.09B | USD 2M | USD 0.0154 | 536.69 | 1.07B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:32:16 | AT | 245 | 827.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/11/2024 | 07:00 | UK RNS | Indivior PLC Transaction in Own Shares |
| 18/11/2024 | 08:48 | UK RNS | Indivior PLC Holding(s) in Company |
| 15/11/2024 | 07:00 | UK RNS | Indivior PLC Director Declaration |
| 12/11/2024 | 07:00 | UK RNS | Indivior PLC Transaction in Own Shares |
| 11/11/2024 | 14:29 | UK RNS | Indivior PLC Holding(s) in Company |
| 08/11/2024 | 16:50 | UK RNS | Indivior PLC Block listing Interim Review |
| 08/11/2024 | 09:55 | ALNC |  Indivior to talk with Oaktree after accusations of "value destruction" |
| 08/11/2024 | 07:00 | UK RNS | Indivior PLC Indivior Responds to Letter from Oaktree |
| 05/11/2024 | 11:19 | ALNC | Indivior completes refinancing of secured term loan |
| 05/11/2024 | 07:00 | UK RNS | Indivior PLC Indivior Completes Refinance of Secured Term Loan |
Indivior (INDV) Share Charts1 Year Indivior Chart |
|
1 Month Indivior Chart |
Intraday Indivior Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 08/11/2024 | 14:09 | INDIVIOR THE PILL WITH NO CHEERS OR BEERS | 4,222 |
| 09/3/2020 | 10:34 | RB. de-merger | 548 |
| 11/7/2019 | 07:29 | Johnson & Johnson court case oklahoma | 6 |
| 03/5/2019 | 09:16 | Judgement against insys | 2 |
| 31/7/2018 | 12:45 | Indivior (INDV) IP Battle Status | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:32:16 | 827.50 | 245 | 2,027.38 | AT |
| 08:32:02 | 827.50 | 273 | 2,259.08 | AT |
| 08:32:02 | 828.00 | 3 | 24.84 | AT |
| 08:32:02 | 828.50 | 72 | 596.52 | AT |
| 08:32:02 | 828.50 | 30 | 248.55 | AT |
| Top Posts |
|---|
Posted at 20/11/2024 08:20 by Indivior Daily Update Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 826.50p.Indivior currently has 129,575,205 shares in issue. The market capitalisation of Indivior is £1,070,939,069. Indivior has a price to earnings ratio (PE ratio) of 536.69. This morning INDV shares opened at - |
Posted at 07/11/2024 20:24 by imjustdandy Looks like hostile takeover - article just out Indivior PLC (NASDAQ:INDV) soared 13% amid some takeover speculation as well as a letter from one of its largest holders.Oaktree Capital Management, Indivior's second-largest holder with a 7.5% stake, wrote a letter on Wednesday to the company's board discussing its disappointment with the company's performance."It is unacceptable that Indivior's stock price has plummeted more than 50% in the past year," Andrew Diego West, a managing director at Oaktree wrote in the letter. "In the face of that value destruction, Oaktree has attempted to engage constructively with the Company's Board to address shareholder concerns and improve shareholder value. However, instead of coming to the table collaboratively and demonstrating that they are taking action, the Board and management seem to be doubling down on a failing strategy, ignoring competitive threats and allowing costs to spiral."Indivior (INDV) on Thursday responded to the Oaktree letter."The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation," Indivior said in the statement. "The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy."The Oaktree letter comes after the dual-listed U.S. drugmaker last month lowered its fiscal 2024 guidance for the second time in roughly three months, citing sales headwinds related to Sublocade, a prescription drug indicated for opioid use disorder.There's also speculation that the British biotech company may have attracted takeover interest, according to traders, who cited a Betaville "uncooked" alert that was circulating on Thursday. |
Posted at 07/11/2024 20:17 by imjustdandy Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of IndiviorSource: PR Newswire (US)RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.Indivior (PRNewsfoto/Indivior |
Posted at 07/11/2024 19:03 by imjustdandy Board of DirectorsIndivior PLC 10710 Midlothian Turnpike, Suite 125 North Chesterfield, Virginia 23235 To the Members of the Board of Directors: As you know, Oaktree Capital Management, L.P. (“Oaktree̶ It is unacceptable that Indivior’s stock price has plummeted more than 50% in the past year. In the face of that value destruction, Oaktree has attempted to engage constructively with the Company’s Board to address shareholder concerns and improve shareholder value. However, instead of coming to the table collaboratively and demonstrating that they are taking action, the Board and management seem to be doubling down on a failing strategy, ignoring competitive threats and allowing costs to spiral. The Board and management’s actions, or lack thereof, have caused Indivior to underperform the S&P Composite 1500 Pharmaceuticals Select Industry Index by (68%), (71%) and (77%), over a 1-year, 2-year and 3-year period respectively.1 Rather than focusing on Indivior’s core product, Sublocade, the Company spent valuable time and money on unproductive acquisitions, a now-discontinued business line, and excessive R&D. All the while, the Company essentially disregarded Brixadi’s entrance into the market by failing to take basic steps to protect Sublocade’s competitive position. As an example, the Company waited seven years after Sublocade’s initial FDA approval and more than a year after its competitor’s entry into the market before submitting its prior approval supplements to the FDA for Rapid Induction and Alternative Injection Sites – a pivotal step that would have solidified Sublocade’s dominant position and subdued the competitive threat from Brixadi. As a result, shareholders have suffered a more than 50% loss. Indivior’s communications regarding its 2024 financial guidance serve as a telling example. At Indivior’s May 23, 2024 analyst teach-in event, management reiterated its full-year and long-term guidance metrics. Six weeks after that, management lowered its financial guidance: they cited Medicaid redetermination and a litany of other reasons but continued to dismiss the increasingly obvious competitive threat from Brixadi. Five months later, management took down guidance again, finally appearing to acknowledge an aggressive competitor. Management either didn’t recognize the competitive threat, or worse, they failed to appropriately alert the investing public about it. To be clear, we strongly believe in the Company’s mission to alleviate the severe human suffering brought about by the opioid crisis and Sublocade’s key role. However, the rapid decline of shareholder value and the events of the past year – including a lack of focus and accountability by the Board and management, as well as failure to recognize and counter such a clear competitive threat – have exacerbated investor concerns around the Company’s strategy and the Board’s willingness and ability to hold management accountable. 1 As of November 5, 2024. 1 Oaktree Capital Management, L.P. 333 South Grand Avenue, 28th floor Los Angeles, CA 90071 p +1 213 830-6300 oaktreecapital.com The Company must take immediate steps to address the following key concerns: 1) Fix Capital Allocation Strategy and Cost Structure Indivior’s capital allocation strategy has not produced results. • Opiant: the Company acquired Opiant in March 2023 for $145 million, which has yet to generate meaningful revenue from its key product, Opvee, despite it receiving FDA approval in May 2023. • Perseris: after significant R&D and operational expenses, management announced that it would discontinue sales and marketing of the product in July 2024, less than two months after reiterating guidance of peak sales of $200 to $300 million. • Manufacturing site: an $85 million investment2 to insource Sublocade and Perseris production seems misguided given the fate of Perseris and the minimal existing internal manufacturing process and know-how. Indivior’s cost structure is bloated. • Costs continue to soar: from fiscal-year 2018 to 2023,adjusted operating expenses have increased by over 19% while revenue increased by only 4%.3 • Operating expenses far exceed peers: Indivior’s operating expenses (excluding R&D) as a percentage of revenue have averaged almost 1400 basis points higher than its peers over the last five years.4 2) Hold Management Accountable The Company’s pattern of missteps must end. • The Board seemingly failed to push management to prepare for Brixadi’s market entry, despite common understanding of Brixadi’s desire (dating as far back as 2014) to compete with Sublocade in the U.S. market. Furthermore, the Company: o Failed to timely counter potential, but addressable, weaknesses of Sublocade (the drug’s shelf life and FDA approval for rapid induction and alternate injection sites). o Didn’t appropriately prepare for competition in the criminal justice system channel, which led to the Company losing a material contract. • The management team has fallen short in its communication with the market, consistently understating material financial impacts, often despite direct questions on the subject. For example, they: o Stated there would be no impact on guidance from Medicaid redetermination disenrollments, then a few months later cited these disenrollments as a reason for the Company’s reduction in its financial outlook. o Said there would be no impact on financial performance from competition, then blamed competition for poor financials just a few months later. 2 Per November 9, 2023, investor presentation slide 11: $5.5 million upfront consideration, $30 million in assumed contract liabilities and capital expenditures of $45 to $55mm over the next three years. 3 Figures in aggregate. 4 Peers include Alkermes PLC, Jazz Pharmaceuticals PLC, Supernus Pharmaceuticals Inc., Pacira BioSciences Inc., Neurocrine Biosciences Inc., Collegium Pharmaceutical Inc. and Endo Inc. 2 Oaktree Capital Management, L.P. 333 South Grand Avenue, 28th floor Los Angeles, CA 90071 p +1 213 830-6300 oaktreecapital.com 3) Align Board with Shareholders We are deeply concerned that the Board has failed to hold management, and themselves, accountable for the Company’s failures and destruction of shareholder value. Further, the non-executive members of the Board hold no meaningful amount of stock, and, unlike most U.S.-listed companies, the Company does not promote alignment with shareholders by compensating non-executive directors in stock. We believe that the Board must address these issues immediately and work with us to refresh the Board with directors who are committed to taking all steps necessary to improve shareholder value and hold management accountable as they seek to address the Company’s performance. While we remain interested in working constructively with the Board, we believe it is evident that shareholders are extremely concerned about Indivior’s performance and direction and would support action to effectuate change if necessary. We look forward to continuing our communications in the coming weeks. Andrew Diego West Managing Director Value Opportunities Oaktree Capital Management, L.P. 3 |
Posted at 24/10/2024 11:22 by the grumpy old men Ian LyallPROACTIVENEWS Indivior shares motor 11% after reassuring update; brokers positive Published: 11:50 24 Oct 2024 BST Indivior PLC (LSE:INDV)’s share price jumped 11% after the company reaffirmed its full-year outlook despite recent challenges, including increased competition for its opioid addiction treatment, Sublocade. In its third-quarter results, Indivior posted a 13% revenue increase to $307 million, with Sublocade sales rising 14% to $191 million. The company addressed concerns over competitor Brixadi, stating it remains confident in Sublocade's leadership, which holds a mid-60% market share in key prescribing groups. CEO Mark Crossley highlighted Sublocade’s differentiation, particularly in combating synthetic opioids, and reaffirmed the goal of achieving over $1.5 billion in peak revenue. Indivior is also streamlining its operations, aiming to cut operating expenses by up to $20 million in 2025. "Headline [third quarter figures beat consensus due to strong Suboxone Film but Sublocade growth is flat QoQ [quarter-on-quarter] In late morning trade, the stock was up 74.5p at 725p. Jefferies says 'buy' up to 1,800p. Fellow American bank Stifel restated its 'buy' and 1,400p price target, adding: "We are encouraged by the still more than 60% share for Sublocade by co-prescribers of both Sublocade and Brixadi, while the early and within-expectations settlement of the remaining antitrust cases is incrementally positive. "After two profit warnings this year, we recognise the need to rebuild market confidence, but continue to believe market concerns implied by current low multiples...are overdone." |
Posted at 24/10/2024 10:16 by martinmc123 4*Indivior posted upbeat Q3 results and also announced that it had reached an expected settlement with certain end payors to resolve remaining antitrust cases. Total Q3 2024 net revenue (NR) of $307m was up +13% vs. Q3 2023 with ytd revenue up 11% to $889m. Of this SUBLOCADE® Q3 2024 NR of $191m was +14% vs. Q3 2023 taking YTD 2024 SUBLOCADE NR up to $562m which was +24% vs. YTD 2023. The impressive top line performance fed down to improved bottom line performance, Q3 2024 reported net income was $4m up from a Q3 2023... ...from WealthOracle wealthoracle.co.uk/d |
Posted at 21/10/2024 07:39 by tsmith2 Slough, UK, and Richmond, VA, October 15, 2024 - Indivior PLC (NASDAQ/LSE: INDV) today announced that it will release its year-to-date and Q3 2024 results on October 24th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.Mar |
Posted at 10/10/2024 17:49 by waldron Benjamin ChiouSharecast News 10 Oct, 2024 17:01 Europe close: Stocks inch lower after choppy session Thursday saw choppy trading across European stock markets with the region's main benchmark finishing lower but moving within a narrow range, as investors focused on mixed economic data from the US and developments in the Middle East. The Stoxx 600 index closed down 0.18% (0.94 points) at 519.11, with less than four points separating the intraday high (521.08) and low (517.81). Wall Street stocks got off to a weak start after inflation and jobless claims data blurred the outlook for the next Federal Reserve policy decision. Following last week's bumper payroll report, markets had begun to lower their expectations for another big rate cut from the Fed. But data out on Thursday showed that jobless claims had jumped to their highest since June 2023, reviving hopes that more policy action could be on the cards to ease the strain on the economy. Nevertheless, figures showed that the annual rate of US consumer price inflation slowed to a three-and-a-half-yea Meanwhile, oil prices were once again on the rise as tensions in the Middle East continued to escalate. Brent was up 2.1% at $78.19 a barrel by the close in Europe, after having pulled back sharply over recent days since topping the $80 mark on Monday. “It looks increasingly likely that Israel will go for a large-scale attack on Iran, as reports emerge of Gulf states lobbying the US to rein in its ally," said Chris Beauchamp, chief market analyst at IG. "Oil prices have surged on hints that Israel is seeking to take advantage of the Iranian attack to deliver a major strike on its opponent. The consequences of that could include a closing of the Straits of Hormuz, leading to major disruption to oil supplies.” Back in Europe, data showed that retail sales in Germany rose over the past two months. According to delayed data from the Federal Statistical Office, sales volumes increased by 1.6% during August, following a 1.5% gain in July and a 1.1% decline in June. Destatis released figures for the past three months in one go on Thursday after suspending a number of key economic indicators in May due to a failed IT systems update at the Wiesbaden-based authority. Market movers GSK was among the best performers on the Stoxx 600, rising 3% after the London-listed pharma giant agreed to settle about 93% of US cases in its Zantac lawsuits for up to $2.2bn. The settlement figure was close to the "best case scenario", according to Jefferies, which said the announcement should remove a significant weight on the share price. Deutsche Telekom rose 2% on plans to lift its dividend and buy back shares on the back of better revenue expectations in the next three years. Leading the fallers was UK pharma firm Indivior after delivering its second profit warning this year. Shares were down 19% after Indivior said it was seeing faster initial adoption among treatment providers of a competing long-acting injectable to its Sublocade treatment, as it cut its full-year sales and earnings targets |
Posted at 10/8/2024 05:59 by misca2 Indivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action LawsuitAugust 09, 2024 at 09:54 pm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Indivior PLC (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024. Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders (“OUD”) and serious mental illnesses. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Invidior PLC (INDV) Misled Investors Regarding the Financial Prospects of its Products According to the complaint, during the class period, defendants: (i) grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than Defendants had led investors and analysts to believe; (ii) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company’s anticipated revenue and other financial metrics; (iii) knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY2024 net revenue guidance, including FY2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; and (iv) knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS. On July 9, 2024, Indivior issued a press release "announc[ing] a business update encompassing [its] outlook for [second quarter (‘Q2’)] and FY2024 financial performance." The July 9 Update reduced FY 2024 (i) total net revenue guidance to $1.15-$1.215 billion from the previous ranges of $1.24-$1.33 billion; (ii) SUBLOCADE net revenue guidance to $765-$805 million from the previous range of $820-$880 million; and (iii) OPVEE net revenue guidance to $9-14 million from the previous range of $15-25 million. The July 9 Update also shockingly advised that the Company would immediately cease all sales and marketing activities related to PERSERIS. On this news, Indivior's stock price fell $5.15 per share, or 33.57%, to close at $10.19 per share. What Now: You may be eligible to participate in the class action against Invidior PLC. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by October 1, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against Invidior PLC settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. View source version on businesswire.com: |
Posted at 17/7/2024 09:53 by davius Just been giving Indivior a cursory look...Market cap £1bn, bottom end of expected profit £220m, P/E under 5. $100m a year on share buy backs. A poorly received update. I'm missing something significant. Otherwise the share price fall looks well over done. |
Posted at 12/3/2022 17:05 by typo56 The news is quite possibly a continuation of this from 23 Feb.."Indivior, the FTSE 250-listed opiod addiction treatment company, is rumoured to be the mystery bidder circling Opiant Pharmaceuticals, the US-listed developer of medicines for drug addiction. People following the situation have heard rumours Indivior has been talking to Opiant since December last year year about a possible offer for the company." Good or bad for the INDV share price? You decide! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
